MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial

Additional file 1: Table S1. Change in cell counts from baseline in linagliptin vs. Placebo groups. FMD: flow mediated dilatation; MTT: meal tolerance test; sVCAM-1: soluble vascular cell adhesion molecule-1; sICAM-1: soluble intercellular adhesion molecule-1.